CT 7439
Alternative Names: CT-7439Latest Information Update: 19 Dec 2023
At a glance
- Originator Carrick Therapeutics
- Class Antineoplastics
- Mechanism of Action CDK13 protein inhibitors; Cyclin dependent kinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Sep 2023 Carrick Therapeutics plans a phase I trial in Solid tumours (Late stage disease) (PO) in 1H of 2024
- 07 Sep 2023 The US FDA approves IND application for CT 7439 in Solid tumours
- 14 Jan 2022 CT 7439 is available for licensing as of 14 Jan 2022. https://www.carricktherapeutics.com/partnering/